Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report

Almangour, Thamer A.; Fletcher, Valerie; Alessa, Mohammed; Alhifany, Abdullah A.; Tabb, Deanne

doi:10.12659/ajcr.905930

Cited by 32 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These pharmacokinetic properties turn dalbavancin into a treatment option for gram-positive infections requiring long term treatment such as osteomyelitis or endocarditis. Although clinical trials on complicated bacteremia and osteomyelitis are ongoing (NCT03091439, NCT03426761, NCT03148756) and one study on the treatment of osteomyelitis was recently published (Rappo et al, 2019), reports on the clinical use and therapeutic efficacy of dalbavancin in these indications are scarce (Tobudic et al, 2018;Bouza et al, 2017;Almangour et al, 2017). Bouza et al (2017) conducted a retrospective multicenter study to evaluate clinical experience with dalbavancin in 69 patients in Spain.…”

Section: Discussionmentioning

confidence: 99%

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Wunsch

Krause

Valentin

et al. 2019

International Journal of Infectious Diseases

112

View full text Add to dashboard Cite

Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings. Objectives: To evaluate indications, safety, tolerability and long-term outcomes of dalbavancin-treated patients.Patients and methods Our multicenter, retrospective study includes patients who received dalbavancin in Austria from September 2016 to March 2018. 90-day outcomes and tolerability were determined. Results: A total of 101 patients were included in 3 centers (57% male, median age 65 years). The treated infections were PJI (31%), osteomyelitis (29%), endocarditis (25%) and acute bacterial skin and soft tissue infections (12%). Concomitant use of other antimicrobial substances was common (63%). The mean total cumulative dose of dalbavancin was 3,357 mg (AE2,283 mg). Clinical success rate was 89%. Side effects occurred in 3/101 patients. Conclusion:In this real-life study dalbavancin was primarily used in off-label indications for treatment of PJI, osteomyelitis and endocarditis. Success rate was high (89%), tolerability and safety were excellent in this setting. Dalbavancin may therefore be used in these off-label indications as alternative treatment approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Wunsch

Krause

Valentin

et al. 2019

International Journal of Infectious Diseases

112

View full text Add to dashboard Cite

show abstract

“…As regards off-label use of the drug, studies have been conducted in clinical practice [34][35][36][37][38][39][40][41][42][43][44][45] in patients with osteomyelitis, spondylodiscitis, gram-positive endocarditis, prosthetic infections, septic arthritis, and more generally in all those infections characterized by the presence of an important biofilm, confirming the effectiveness and safety of the drug. In a retrospective study 46 by Morata et al on 64 patients suffering from osteoarticular infections with S. aureus and S. epidermidis, only 7 cases of AEs were observed, including 1 self-limited rash, 3 gastrointestinal problems, 1 asthenia, 1 phlebitis, and 1 case with serum creatinine increase of 0.5 mg/dl.…”

Section: Results -Safetymentioning

confidence: 99%

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Simonetti¹,

Rizzetto²,

Molinelli³

et al. 2021

TCRM

View full text Add to dashboard Cite

Introduction: Dalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Methods: We conducted a narrative review of the literature on the safety profile of dalbavancin. The bibliographic research was carried out on the PubMed database on 6 November 2020 by seeking combinations of the following keywords: dalbavancin, adverse effects, safety, drug interactions, and skin infections. Results: Five double-blind Phase 3 randomized clinical trials, 2 open-label randomized trials, and 4 retrospective studies were identified. No statistically significant differences were found between dalbavancin and comparators in the incidence of adverse events. Retrospective studies confirm the low incidence of adverse events. Conclusion: Dalbavancin is a therapeutic option that has demonstrated an excellent safety profile, also in relation to the other MRSA therapies available. Its use represents a costeffective solution for the treatment of those patients with ABSSSI who would need hospitalization. One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events.

show abstract

“…Также, тедизолид включен в Российские национальные рекомендации по лечению хирургических инфекций кожи и мягких тканей [7,9]. Помимо тедизолида применяются также даптомицин (липопептиды), цефтаролин (цефалоспорины), тигециклин (глицилциклины), телаванцин (гликопептиды) в качестве эпмирической терапии при наличии факторов риска MRSA-инфекции [8,21,45,[47][48][49][50][51].…”

Section: Introductionunclassified

Modern approach to antibacterial therapy in the practice of a surgeon

Морозов

Сергеев

Аскеров

et al. 2021

jour

View full text Add to dashboard Cite

Relevance. Currently, all over the world, antibacterial therapy is widely used as a prophylaxis after surgical interventions. Currently, some data indicate the benefits of a short course, while others, in turn, indicate the benefits of a long course of antibacterial drugs as a prevention of postoperative complications. The problem of pan-resistance of bacterial strains in relation to almost all available groups of antibacterial drugs forces us to look for ways to overcome resistance, to look for new potential bases for the creation of antimicrobial drugs. New antibacterial drugs: odilorhabdins, tridecapeptins and malacidins, arilomycins and others will help to overcome the existing difficulties.The purpose of this study is to analyze the domestic and foreign literature for the period 2017–2021 in order to study the current approach to antibacterial therapy in surgical practice.Material and methods. In the course of this study, publications were selected according to the topic for the period from 2017 to 2021. The information was obtained from foreign and domestic sources: the Russian scientific electronic library, integrated with the Russian Science Citation Index (eLibrary.ru), Medline database (via Pubmed.gov), Scopus database, ScienceDirect database.Results. One of the significant difficulties in the treatment of wounds with antibacterial drugs of various localizations is the persistence of resistant strains of Staphylococcus aureus. In the studied studies, the high effectiveness of tedizolide phosphate in the treatment of this type of infection was noted. It is also possible to use other new drugs as epmiric therapy in the presence of risk factors for MRSA infection: daptomycin (lipopeptides), ceftaroline (cephalosporins), tigecycline (glycylcyclines), telavancin (glycopeptides)[41]. The use of biocides in the treatment of prostheses for hernioplasty as an antibacterial prophylaxis significantly reduces the adhesion of staphylococci and prevents postoperative complications. Suture material with antimicrobial activity, which would allow to fully reduce the risk of infections in the field of surgical intervention, is not yet available on the pharmaceutical market, but the increasing attention of scientists is attracted by chitosan, a derivative of the natural polymer chitin. The combined use of bacteriophages with low doses of antibiotics leads to better results in the treatment of surgical soft tissue infection. Bacteriophages are one of the ways to overcome antibiotic resistance.Conclusions. The modern approach to antibacterial therapy in surgical practice involves the correct and timely appointment of starting therapy, taking into account the sensitivity of microorganisms, the use of antibacterial preoperative prevention, determining the optimal duration of use and dose selection of an antibiotic, the use of sensitive bacteriophages together with them, overcoming antibiotic resistance due to the competent use of new antibacterial drugs based on peptides, a comprehensive approach to the treatment of surgical infection.

show abstract

Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report

Cited by 32 publications

References 17 publications

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Modern approach to antibacterial therapy in the practice of a surgeon

Contact Info

Product

Resources

About